BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 25706866)

  • 1. Antifungal susceptibilities of bloodstream isolates of Candida species from nine hospitals in Korea: application of new antifungal breakpoints and relationship to antifungal usage.
    Won EJ; Shin JH; Choi MJ; Lee WG; Park YJ; Uh Y; Kim SY; Lee MK; Kim SH; Shin MG; Suh SP; Ryang DW
    PLoS One; 2015; 10(2):e0118770. PubMed ID: 25706866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter surveillance of species distribution and antifungal susceptibilities of Candida bloodstream isolates in South Korea.
    Jung SI; Shin JH; Song JH; Peck KR; Lee K; Kim MN; Chang HH; Moon CS;
    Med Mycol; 2010 Jun; 48(4):669-74. PubMed ID: 20392145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between antifungal usage and antifungal susceptibility in clinical isolates of Candida: a multicenter Korean study.
    Kim SH; Shin JH; Kim EC; Lee K; Kim MN; Lee WG; Uh Y; Lee HS; Lee MK; Jeong SH; Jung SI; Park KH; Lee JS; Shin MG; Suh SP; Ryang DW
    Med Mycol; 2009 May; 47(3):296-304. PubMed ID: 18668423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the Vitek 2 yeast susceptibility system with CLSI microdilution for antifungal susceptibility testing of fluconazole and voriconazole against Candida spp., using new clinical breakpoints and epidemiological cutoff values.
    Pfaller MA; Diekema DJ; Procop GW; Rinaldi MG
    Diagn Microbiol Infect Dis; 2013 Sep; 77(1):37-40. PubMed ID: 23870164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison of broth microdilution and E-test methods for the antifungal susceptibility testing of Candida spp. strains isolated from blood cultures].
    Ozcan SK; Mutlu B; Dündar D; Willke A
    Mikrobiyol Bul; 2010 Apr; 44(2):263-71. PubMed ID: 20549961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro fluconazole and voriconazole susceptibilities of Candida bloodstream isolates in Korea: use of the CLSI and EUCAST epidemiological cutoff values.
    Jang MJ; Shin JH; Lee WG; Kim MN; Lee K; Lee HS; Lee MK; Chang CL; Jang HC; Song ES; Kim SH; Shin MG; Suh SP; Ryang DW
    Ann Lab Med; 2013 May; 33(3):167-73. PubMed ID: 23667842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance.
    Xiao M; Fan X; Chen SC; Wang H; Sun ZY; Liao K; Chen SL; Yan Y; Kang M; Hu ZD; Chu YZ; Hu TS; Ni YX; Zou GL; Kong F; Xu YC
    J Antimicrob Chemother; 2015 Mar; 70(3):802-10. PubMed ID: 25473027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009).
    Pfaller MA; Castanheira M; Messer SA; Moet GJ; Jones RN
    Diagn Microbiol Infect Dis; 2010 Nov; 68(3):278-83. PubMed ID: 20846808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.
    Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Ng KP; Colombo A; Finquelievich J; Barnes R; Wadula J;
    J Clin Microbiol; 2008 Mar; 46(3):842-9. PubMed ID: 18199791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of microdilution and disk diffusion methods for the detection of fluconazole and voriconazole susceptibility against clinical Candida glabrata isolates and determination of changing susceptibility with new CLSI breakpoints].
    Hazırolan G; Sarıbaş Z; Arıkan Akdağlı S
    Mikrobiyol Bul; 2016 Jul; 50(3):428-37. PubMed ID: 27525398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest.
    Fleck R; Dietz A; Hof H
    J Antimicrob Chemother; 2007 Apr; 59(4):767-71. PubMed ID: 17293369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. National surveillance of antifungal susceptibility of Candida species in South Korean hospitals.
    Yoo JI; Choi CW; Lee KM; Kim YK; Kim TU; Kim EC; Joo SI; Yun SH; Lee YS; Kim BS
    Med Mycol; 2009; 47(5):554-8. PubMed ID: 18819023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004 to August 2005.
    Borg-von Zepelin M; Kunz L; Rüchel R; Reichard U; Weig M; Gross U
    J Antimicrob Chemother; 2007 Aug; 60(2):424-8. PubMed ID: 17562683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antifungal susceptibility of 1000 Candida bloodstream isolates to 5 antifungal drugs: results of a multicenter study conducted in São Paulo, Brazil, 1995-2003.
    da Matta DA; de Almeida LP; Machado AM; Azevedo AC; Kusano EJ; Travassos NF; Salomão R; Colombo AL
    Diagn Microbiol Infect Dis; 2007 Apr; 57(4):399-404. PubMed ID: 17240110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole.
    Espinel-Ingroff A; Barchiesi F; Cuenca-Estrella M; Pfaller MA; Rinaldi M; Rodriguez-Tudela JL; Verweij PE
    J Clin Microbiol; 2005 Aug; 43(8):3884-9. PubMed ID: 16081926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values.
    Pfaller MA; Chaturvedi V; Diekema DJ; Ghannoum MA; Holliday NM; Killian SB; Knapp CC; Messer SA; Miskou A; Ramani R
    Diagn Microbiol Infect Dis; 2012 Aug; 73(4):365-8. PubMed ID: 22726528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Species distribution and antifungal susceptibility of bloodstream fungal isolates in paediatric patients in Mexico: a nationwide surveillance study.
    González GM; Treviño-Rangel Rde J; Palma-Nicolás JP; Martínez C; González JG; Ayala J; Caballero A; Morfín-Otero R; Rodríguez-Noriega E; Velarde F; Ascencio EP; Tinoco JC; Vázquez JA; Cano MA; León-Sicairos N; González R; Rincón J; Elías MA; Bonifaz A
    J Antimicrob Chemother; 2013 Dec; 68(12):2847-51. PubMed ID: 23869052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida.
    Pfaller MA; Diekema DJ;
    Clin Microbiol Infect; 2004 Mar; 10 Suppl 1():11-23. PubMed ID: 14748799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.
    Seifert H; Aurbach U; Stefanik D; Cornely O
    Antimicrob Agents Chemother; 2007 May; 51(5):1818-21. PubMed ID: 17307977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.